Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader advised HealthCare Royalty Partners on a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases. https://www.cadwalader.com/news/news-release/cadwalader-advises-healthcare-royalty-partners-on-revenue-financing-agreement-with-spero-therapeutics